US Patent No: 8,052,974

Number of patents in Portfolio can not be more than 2000

Host cell specific binding molecules capable of neutralizing viruses and uses thereof

Stats

ALSO PUBLISHED AS: 20100303801
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The present invention provides human binding molecules specifically binding to a host cell protein and having virus neutralizing activity, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis and/or treatment of viral infections.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
CRUCELL HOLLAND B.V.LEIDEN131

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
De, Kruif Cornelis Adriaan De Bilt, NL 38 73
Throsby, Mark Utrecht, NL 25 34

Cited Art

Patent Info (Count) # Cites Year
 
CRUCELL HOLLAND B.V. (6)
6,265,150 Phage antibodies 68 1998
7,425,437 Vaccines against West Nile Virus 3 2005
7,537,764 Binding molecules capable of neutralizing west nile virus and uses thereof 4 2006
2009/0054,254 Method for Preparing Immunoglobulin Libraries 4 2006
7,244,430 Binding molecules capable of neutralizing West Nile virus and uses thereof 4 2007
2009/0017,068 Vaccines against West Nile Virus 3 2008
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (3)
5,494,671 C-terminally truncated dengue and Japanese encephalitis virus envelope proteins 29 1991
6,184,024 Chimeric and/or growth-restricted flaviviruses 37 1994
6,685,948 Replication-defective dengue viruses that are replication-defective in mosquitoes for use as vaccines 5 2001
 
VIROGENETICS CORPORATION (3)
5,514,375 Flavivirus recombinant poxvirus vaccine 29 1991
5,744,140 Flavivirus recombinant poxvirus vaccine 12 1994
5,744,141 Flavivirus recombinant poxvirus immunological composition 16 1995
 
ALEXION PHARMACEUTICALS, INC. (2)
2004/0009,178 Immunotherapeutics for biodefense 11 2003
2004/0258,699 Immunotherapeutics for biodefense 13 2003
 
MERCK SHARP & DOHME CORP. (2)
6,416,763 Recombinant nonstructural protein subunit vaccine against flaviviral infection 10 1998
6,432,411 Recombinant envelope vaccine against flavivirus infection 6 1999
 
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (2)
6,258,788 DNA vaccines against tick-borne flaviviruses 13 1998
6,875,433 Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein 7 2002
 
ABBVIE INC. (1)
7,491,516 Dual specificity antibodies and methods of making and using 8 2001
 
BAXTER INTERNATIONAL INC. (1)
2004/0077,086 Animal protein free media for cultivation of cells 7 2003
 
ELI LILLY AND COMPANY (1)
5,696,108 Protein kinase C inhibitors 10 1996
 
GENENTECH, INC. (1)
6,331,415 Methods of producing immunoglobulins, vectors and transformed host cells for use therein 156 1988
 
IDEXX LABORATORIES, INC. (1)
7,074,555 Detection of West Nile Virus 4 2004
 
MACROGENICS, INC. (1)
2006/0057,149 Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof 4 2005
 
MOCHIDA PHARMACEUTICAL CO., LTD. (1)
2007/0025,992 Monoclonal antibody against platelet membrane glycoprotein VI 7 2004
 
NEW YORK HOSPITAL MEDICAL CENTER OF QUEENS, THE (1)
6,946,125 Methods of treating West Nile virus infection 5 2001
 
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (1)
6,455,509 Dengue nucleic acid vaccines that induce neutralizing antibodies 15 1997
 
WASHINGTON UNIVERSITY (1)
2006/0067,940 Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof 8 2005
 
WYETH (1)
2006/0269,571 Equine West Nile virus immunotherapy 3 2005
 
YANG MING UNIVERSITY (1)
6,306,899 Inhibition and treatment of Hepatitis B virus and Flavivirus by Helioxanthin and its analogs 7 1999
 
ZOETIS W LLC (1)
7,153,513 West nile vaccine 2 2002
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (2)
2003/0148,261 Compositions and methods comprising West Nile virus polypeptides 11 2002
2006/0115,837 Crystals and structure of domain III of West Nile Virus envelope protein in association with a Fab fragment of a neutralizing antibody 6 2005

Patent Citation Ranking

Forward Cites

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 8, 2015
7.5 Year Payment $3600.00 $1800.00 $900.00 May 8, 2019
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 8, 2023
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00